Share Price:

APNASPENAspen Pharmacare Hldgs1699583 (0.49%)
Our Response to Covid
Country Sites

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Regional Overviews

Aspen in Europe CIS

The Europe CIS region provides a diverse range of Injectables, Prescription, and OTC brands, and is also involved in third-party manufacturing. Manufacturing operations account for 72% of the region’s revenue, focusing on API and FDF production for third-party use, while also supplying Aspen’s own needs. The Commercial Pharmaceuticals portfolio primarily includes contributions from OTC and Injectables, with a smaller share from Prescription products.

Key Countries

France
Germany
Italy
Sweden
United Kingdom

Overview

Learn More
Brand Therapeutic category
Diprivan

General anaesthetic
Emla

Topical anaesthetic

Ovestin

Estrogen hormone replacement

Ultiva

Opioid analgesic
Xylocaine topicals

Topical anaesthetic
0
Products
Launched

(2023: 5)

0
Product
Recalls

(2023: 2)

0 %
Average Staff
Turnover

(2023: 11%)

0
Work-related
Facilities

(2023: Nil)

90
Sales
Representatives

(2023: 131)

400
Permanent
Employees

(June 2024)

400
Permanent
Employees

(June 2023)

Products
Launched

(2022: Nil)

0
Product
Recalls

(2022: 5)

0 %
Average Staff
Turnover

(2022: 9%)

Work-related
Facilities

(2022: Nil)

50
Sales
Representatives

(2022: 140)

900
Permanent
Employees

(June 2022: 2,192)

Revenue 2024
R’million		 2023 (CER)
R’million		 Change
%

Commercial Pharmaceuticals

4 868

5 148

(5)
Over the counter

1 974

1 838

7

Injectables

1 903

2 243

(15)

Prescription

991

1 067

(7)

Manufacturing

12 735

10 619

20

Active Pharmaceutical Ingredients

4 832

5 231

(8)

Finished dose form

4 131

2 885

43

Heparin

3 772

2 503

51
Total

17 603

15 767

12

Note: Commercial Pharmaceuticals’ revenue is by customer geography and Manufacturing revenue is by
place of manufacture.

Contribution to Group revenue (%)
  • Rest of Group 60
  • Europe CIS40
Revenue by segment (%)
  • Active pharmaceutical ingredients 28
  • Finished dose form 23
  • Heparin 21
  • Injectables11
  • Over the counter11
  • Prescription 6
  • Eastern and Western Europe are expected to grow 1,6% and 1,1% CAGR between 2024 and 2028.

Source: IQVIA Institute, December 2023.

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.